CN113544143A - 用于治疗涉及cxcl1功能的疾病的组合物和方法 - Google Patents

用于治疗涉及cxcl1功能的疾病的组合物和方法 Download PDF

Info

Publication number
CN113544143A
CN113544143A CN202080017507.1A CN202080017507A CN113544143A CN 113544143 A CN113544143 A CN 113544143A CN 202080017507 A CN202080017507 A CN 202080017507A CN 113544143 A CN113544143 A CN 113544143A
Authority
CN
China
Prior art keywords
antibody
ser
antigen
amino acid
gly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080017507.1A
Other languages
English (en)
Chinese (zh)
Inventor
查尔斯·J·罗瑟
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CN113544143A publication Critical patent/CN113544143A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/521—Chemokines
    • G01N2333/522—Alpha-chemokines, e.g. NAP-2, ENA-78, GRO-alpha/MGSA/NAP-3, GRO-beta/MIP-2alpha, GRO-gamma/MIP-2beta, IP-10, GCP-2, MIG, PBSF, PF-4 or KC
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
    • G01N2800/102—Arthritis; Rheumatoid arthritis, i.e. inflammation of peripheral joints
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/20—Dermatological disorders
    • G01N2800/205—Scaling palpular diseases, e.g. psoriasis, pytiriasis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7014—(Neo)vascularisation - Angiogenesis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202080017507.1A 2019-01-28 2020-01-28 用于治疗涉及cxcl1功能的疾病的组合物和方法 Pending CN113544143A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962797573P 2019-01-28 2019-01-28
US62/797,573 2019-01-28
PCT/US2020/015457 WO2020160022A1 (en) 2019-01-28 2020-01-28 Compositions and methods for treatment of diseases involving cxcl1 function

Publications (1)

Publication Number Publication Date
CN113544143A true CN113544143A (zh) 2021-10-22

Family

ID=71841416

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080017507.1A Pending CN113544143A (zh) 2019-01-28 2020-01-28 用于治疗涉及cxcl1功能的疾病的组合物和方法

Country Status (6)

Country Link
US (3) US11292832B2 (https=)
EP (1) EP3917949A4 (https=)
JP (1) JP2022517865A (https=)
CN (1) CN113544143A (https=)
CA (1) CA3127943A1 (https=)
WO (1) WO2020160022A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3249959A1 (en) * 2022-01-27 2025-06-17 Chiome Bioscience Inc. ANTI-CXCL1 HUMAN ANTIBODY
WO2026060413A1 (en) * 2024-09-16 2026-03-19 Calgent Biotechnology Co., Ltd. Single chain antibodies and use thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7910316B2 (en) * 2005-09-02 2011-03-22 Toray Industries, Inc. Kit and method for detecting urothelial cancer
US7858752B2 (en) 2006-12-05 2010-12-28 Abbott Laboratories Recombinant antibodies against hepatitis C virus and methods of obtaining and using same
CN101261275A (zh) * 2008-01-23 2008-09-10 李力 一种用于早期卵巢癌诊断的检测试剂盒
WO2010050552A1 (ja) 2008-10-29 2010-05-06 日本ゼオン株式会社 ニトリル共重合体ラテックス組成物およびニトリル共重合体ゴム組成物
KR101682257B1 (ko) 2008-10-31 2016-12-05 도레이 카부시키가이샤 인간 ｃｘｃｌ１ 단백질의 면역학적 측정 방법
US8900588B2 (en) 2010-01-08 2014-12-02 Les Laboratories Servier Methods for treating breast cancer
WO2014113804A1 (en) * 2013-01-21 2014-07-24 Abbvie Inc. Anti-tnf and anti-il17 combination therapy biomarkers for inflammatory disease
US9290570B2 (en) 2013-03-15 2016-03-22 Eli Lilly And Company Pan-ELR+ CXC Chemokine Antibodies
EP2997042B1 (en) 2013-05-17 2019-08-07 Centre National de la Recherche Scientifique (CNRS) Anti-cxcl1, cxcl7 and cxcl8 antibodies and their applications
WO2019055776A2 (en) * 2017-09-14 2019-03-21 Rosser Charles COMPOSITIONS AND METHODS FOR TREATING DISEASES INVOLVING CXCL1 FUNCTION
US11603569B2 (en) * 2018-03-20 2023-03-14 Cedars-Sinai Medical Center Immune modulating genes for prognosis, diagnosis and treatment of metastatic disease, and drug identification methods thereof

Also Published As

Publication number Publication date
US20240018229A1 (en) 2024-01-18
EP3917949A1 (en) 2021-12-08
JP2022517865A (ja) 2022-03-10
EP3917949A4 (en) 2022-11-23
CA3127943A1 (en) 2020-08-06
US11292832B2 (en) 2022-04-05
US11760796B2 (en) 2023-09-19
WO2020160022A1 (en) 2020-08-06
US20210301007A1 (en) 2021-09-30
US20220267430A1 (en) 2022-08-25

Similar Documents

Publication Publication Date Title
JP7222987B2 (ja) 抗ｒｏｒ１抗体とその作製及び使用方法
RU2568051C2 (ru) АНТИТЕЛА К ErbB3
JP6513728B2 (ja) Ｈｅｒ３に特異的な結合分子及びそれらの使用
US20220162331A1 (en) Anti-cd73 monoclonal antibody and application thereof
JP2022106751A (ja) ＧＵＣＹ２ｃに特異的な抗体及びその使用
JP6359372B2 (ja) ＤＡＲＰｉｎを含む二重特異キメラ蛋白質
CN102421802B (zh) 人源化的axl抗体
US20110129483A1 (en) Membrane transporter NaPi2b (SCL34A1) epitope for antibody therapy, antibodies directed thereto, and target for cancer therapy
JP2021088593A (ja) 癌治療のための抗ｆａｍ１９ａ５抗体の用途
JP2017518958A (ja) 免疫原性グリコペプチドに対する抗体、それを含む組成物、及びそれらの使用
CN114269782B (zh) 抗tigit抗体及其应用
JP2022502417A (ja) 抗ｏｘ４０抗体、その抗原結合フラグメント、および医薬用途
EP3192813A1 (en) Humanized monoclonal antibody for inhibiting vascular endothelial lipase enzyme activity
US20240018229A1 (en) Compositions and methods for treatment of diseases involving cxcl1 function
KR102477179B1 (ko) 위암의 검출 및 치료를 위한 조성물 및 방법
KR102773176B1 (ko) 암 치료용 안티-서비빈 항체
US20220169714A1 (en) Compositions and methods for treatment of diseases involving cxcl1 function
AU2014412643B2 (en) Novel EGFRvIII antibody and composition comprising same
CN114127120A (zh) 抗-碳酸酐酶ix抗体
KR101854529B1 (ko) 인간 및 마우스 Ｓｅｍａ３Ａ에 교차결합하는 항체 및 그의 용도
JP7854016B2 (ja) 腫瘍治療薬及びその応用
WO2024241997A1 (ja) がんを治療又は予防するための医薬組成物
WO2025172588A1 (en) Bispecific constructs directed against fap and ltbr
CN121057749A (zh) 抗cd3多特异性抗体和使用方法
JP2024167313A (ja) 腫瘍治療薬及びその応用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination